Trials in North Carolina.
68 APOE4-relevant Alzheimer’s trials run in North Carolina — 34 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Built exclusively for APOE4 homozygotesNCT03634007Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
This Phase 1 trial is testing LX1001, a gene therapy delivered into the spinal fluid, in people who carry two copies of APOE4 and already have…
- APOE4 genotype central to studyNCT03876314Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype
This trial is testing whether a structured physical activity program improves cognitive performance in middle-aged adults (40-65) who have a family history of…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Built exclusively for APOE4/4 carriersNCT04770220An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
This Phase 3 trial is testing ALZ-801, an oral drug designed to reduce toxic amyloid clusters in the brain, against a placebo in people with early Alzheimer's…
- General AD trial, no APOE4 focusNCT00265148Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease
This Phase 2 trial tested rosiglitazone, a drug originally developed for type 2 diabetes, against a placebo in people with mild to moderate Alzheimer's…
- APOE4 enrolled, response may differNCT00348140Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- Open to carriers, not 4-specificNCT00710684A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease
This trial tested SB-742457, an experimental drug added on top of donepezil, the standard Alzheimer's medication, in people with mild-to-moderate Alzheimer's…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Open to carriers, not 4-specificNCT02814526Exercise in Adults With Mild Memory Problems
This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…
- Unrelated to APOE4 or Alzheimer'sNCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity is collecting cerebrospinal fluid and blood samples from people at various stages of Huntington's disease, plus healthy controls, across multiple…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Unrelated to APOE4 or Alzheimer'sNCT03047369The Myelin Disorders Biorepository Project
This is a biorepository project, not a treatment trial. Researchers are collecting medical records and biological samples (like blood or tissue) from people…
- Explicitly lists APOE4-positive carriersNCT03233646Retinal Imaging in Neurodegenerative Disease
This study uses non-invasive eye-imaging technology — optical coherence tomography (OCT) and wide-field retinal photography — to look for early signs of…
- Unrelated to APOE4 riskNCT03754725Ferritin and Iron Burden in SAH sIRB
This trial is testing whether deferiprone, an oral drug that removes iron from the body, can reduce iron buildup in the brain after a ruptured brain aneurysm…
- Open to carriers, not 4-specificNCT03848312Preventing Alzheimer's With Cognitive Training
This Phase 3 trial is testing whether a specific type of computerized brain training — called speed of processing training — can delay the onset of mild…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Open to carriers, genotype not trackedNCT04098666Metformin in Alzheimer's Dementia Prevention
This trial is testing whether extended-release metformin, a widely used diabetes drug, can slow memory decline in people who are overweight and already showing…
- Open to carriers, not 4-specificNCT04148391NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
This trial is testing NYX-458, an experimental oral drug, against a placebo in people who have mild cognitive impairment or mild dementia caused by Parkinson's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Unrelated to APOE4 or Alzheimer'sNCT05144516Cancer and Mild Cognitive Impairment Dyadic Intervention
This trial is testing a behavioral support program called COPE+ for pairs of people — one with cancer and mild memory difficulties, plus their spouse or family…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Open to carriers, not 4-specificNCT05460468Neuromodulation of Memory in Aging
This trial is testing whether a non-invasive brain stimulation technique called closed-loop TMS can improve working memory in healthy older adults and people…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, genotype not requiredNCT05507905Effects of Dance and Music Appreciation on Brain Health and Fitness in People at Risk for Alzheimer's Disease
This trial is testing whether dance classes or music appreciation sessions help protect memory and cardiovascular fitness in older adults worried about memory…
- Closed follow-up, genotype not a factorNCT05532657ACHIEVE Brain Health Follow-Up Study
This trial is a 3-year follow-up to a completed study called ACHIEVE. It is tracking whether older adults who received hearing aids earlier show less cognitive…
- Open to carriers, not 4-specificNCT05741060Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
This Phase 2 trial is testing whether a daily soy-derived supplement called S-equol can slow the stiffening of arteries, reduce small blood vessel damage in…
- Open to carriers, not 4-specificNCT05771844Home Sleep Therapy for Older Adults With MCI
This trial is testing a home-use device called SleepWISP that delivers gentle, non-invasive electrical stimulation to the brain during sleep. The goal is to…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, not 4-specificNCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…
- Dementia stage only, genotype-blindNCT06088810The Impact of Music Intervention on Sleep
This trial is testing a personalized music app called CoMPoSER, designed to play calming music at bedtime to help people living with dementia sleep better.…
- Open to carriers, not 4-specificNCT06223360A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
This trial is testing benfotiamine — a fat-soluble form of vitamin B1 — at two different doses against a placebo, in people who already have early Alzheimer's…
- Caregiver study, not carrier-focusedNCT06239688Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
This trial is testing two versions of an online dementia care training program for staff at assisted living facilities. One group gets the essentiALZ training…
- Open to carriers, not 4-specificNCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…
- Open to carriers, genotype not studiedNCT06495190Cognition, Flavonoids, Exercise, Gut Microbiome
This NIH-funded trial is testing whether eating blueberries daily for 12 weeks, combined with regular brisk walking, slows mild age-related cognitive decline…
- Open to carriers, not 4-specificNCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…
- Dementia caregiving focus, not preventionNCT06565169Improving PCP Advance Care Planning for People With ADRD
This trial tests a structured toolkit designed to help primary care doctors and nurses have better conversations about future care wishes with people who…
- Open to carriers, not 4-specificNCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…
- Open to carriers, not 4-specificNCT06601933Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
This trial is testing whether doing crossword puzzles frequently (4 times a week) improves cognition and daily functioning better than doing them rarely (once…
- Observational only, genotype not requiredNCT06703541ADRC Clinical Cohort (Alzheimer's Disease)
This is an observational research cohort at Duke and UNC, not a treatment trial. Researchers are enrolling people ages 25 to 80, with or without memory…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.